March's top stories: Novartis' Phase III study, Boehringer's Respimat trial

Novartis' Phase III study of Jakavi met its primary endpoint of maintaining haematocrit control without the need for phlebotomy and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea while Boehringer rep…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news